SPERO THERAPEUTICS INC (NASDAQ:SPRO) reported its second-quarter 2025 financial results, delivering a mixed performance relative to analyst expectations. The clinical-stage biopharmaceutical company, focused on rare diseases and multi-drug resistant bacterial infections, posted revenue of $14.19 million for the quarter, significantly surpassing the consensus estimate of $0. However, the company reported a loss per share of $0.03, which was notably better than the anticipated loss of $0.3876 per share.
Key Financial Highlights
- Revenue: Reported $14.19 million vs. $0 analyst estimate.
- Earnings Per Share (EPS): Reported -$0.03 vs. estimated -$0.3876.
- Market Reaction: Shares fell approximately 6.8% in after-hours trading, despite the earnings beat.
Business Update and Clinical Progress
The company provided updates on its clinical pipeline, most notably the early stoppage of its PIVOT-PO Phase 3 trial evaluating tebipenem HBr for complicated urinary tract infections (cUTI) due to efficacy. This development could position SPRO for a potential regulatory submission, pending further data analysis.
Analyst Estimates and Forward Outlook
Looking ahead, analysts project:
- Q3 2025 Revenue Estimate: $0
- Q3 2025 EPS Estimate: -$0.3978
- Full-Year 2025 Revenue Estimate: $6.018 million
- Full-Year 2025 EPS Estimate: -$1.173
The lack of forward guidance in the press release leaves investors reliant on analyst expectations, which remain cautious given the company’s clinical-stage status and cash burn.
Market Reaction Analysis
Despite beating both revenue and EPS estimates, the stock declined in after-hours trading. This could reflect profit-taking following recent volatility, skepticism about long-term revenue sustainability, or broader sector weakness. Over the past month, SPRO shares have declined nearly 16.7%, indicating persistent investor caution.
For a deeper dive into SPRO’s earnings and estimates, visit SPRO Earnings & Estimates.
Disclaimer: This article is for informational purposes only and does not constitute investment advice.
